Effects of Subchronic Phencyclidine (PCP) Treatment on Social Behaviors, and Operant Discrimination and Reversal Learning in C57BL/6J Mice.
Jonathan L Brigman, Jessica Ihne, Lisa M Saksida, Timothy J Bussey, Andrew Holmes
Frontiers in Behavioral Neuroscience 2009 DOI: 10.3389/neuro.08.002.2009 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | C57BL/6J mice |
| Intervention | Phencyclidine (PCP) |
| Dose | 5 mg/kg twice daily x 7 days |
| Duration | 7-day treatment, 7-day withdrawal |
| Keywords | Nmda Executive function Glutamate Mouse Negative symptoms Prefrontal cortex Psychosis Schizophrenia |
| Key findings | Subchronic PCP treatment in mice increased social approach behaviors but did not impair visual discrimination or reversal learning. |
Abstract
Subchronic treatment with the psychotomimetic phencyclidine (PCP) has been proposed as a rodent model of the negative and cognitive/executive symptoms of schizophrenia. There has, however, been a paucity of studies on this model in mice, despite the growing use of the mouse as a subject in genetic and molecular studies of schizophrenia. In the present study, we evaluated the effects of subchronic PCP treatment (5 mg/kg twice daily x 7 days, followed by 7 days withdrawal) in C57BL/6J mice on (1) social behaviors using a sociability/social novelty-preference paradigm, and (2) pairwise visual discrimination and reversal learning using a touchscreen-based operant system. Results showed that mice subchronically treated with PCP made more visits to (but did not spend more time with) a social stimulus relative to an inanimate one, and made more visits and spent more time investigating a novel social stimulus over a familiar one. Subchronic PCP treatment did not significantly affect behavior in either the discrimination or reversal learning tasks. These data encourage further analysis of the potential utility of mouse subchronic PCP treatment for modeling the social withdrawal component of schizophrenia. They also indicate that the treatment regimen employed was insufficient to impair our measures of discrimination and reversal learning in the C57BL/6J strain. Further work will be needed to identify alternative methods (e.g., repeated cycles of subchronic PCP treatment, use of different mouse strains) that reliably produce discrimination and/or reversal impairment, as well as other cognitive/executive measures that are sensitive to chronic PCP treatment in mice.
Citations in the library
Cited by 12
- Effects of hallucinogenic agents mescaline and phencyclidine on zebrafish behavior and physiology Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2012
- Understanding the role of the NMDA receptor subunit, GluN2D, in mediating NMDA receptor antagonist-induced behavioral disruptions in male and female mice. Journal of Neuroscience Research 2024
- Cerebellar Kv2.1 Downregulation, Cytoarchitectural Alterations, and Persistent Motor Impairments Following Subchronic Phencyclidine Exposure. Neuropharmacology June 1, 2026
- Deficits in medial prefrontal cortex parvalbumin expression and distraction-dependent memory in rats and mice in the sub-chronic phencyclidine model for schizophrenia Frontiers in Cellular Neuroscience October 29, 2025
- Disruptions of the oxytocin system impair sociability and cognitive flexibility in a subchronic phencyclidine model of schizophrenia. Neuropharmacology April 1, 2025
and 7 more in the library
Cites 6
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors. Behavioural Brain Research August 5, 2008
- Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats--a preliminary investigation. Behavioural Brain Research March 5, 2008
- The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behavioural Brain Research May 15, 2006
- The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. Journal of Psychopharmacology March 1, 2003
and 1 more in the library